N/A
18 Years
90 Years
18 Years
90 Years
Not Enrolling
Both
Lymphomas
Both
Lymphomas
Trial Information
Autologous CIK transfusion within 3 days post CD20 antibody treatment.
Inclusion Criteria:
- diagnosed as B-cell lymphoma with CD20 positiveness, and need to therapy
Exclusion Criteria:
- to refuse the therapy and need not tolerate the therapy
Type of Study:
Observational [Patient Registry]
Study Design:
Observational Model: Case Control, Time Perspective: Prospective
Outcome Measure:
disease free survival
Outcome Time Frame:
5 years
Safety Issue:
Yes
Authority:
China: General Hospital of PLA
Study ID:
BT-004
NCT ID:
NCT01828008
Start Date:
April 2013
Completion Date:
May 2015
Related Keywords:
- Lymphomas
- Mabthera
- cytokine induced killer cell
- Lymphoma
Name | Location |
|---|
